Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 446-220-4 | CAS number: 365411-50-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxicokinetic data are available for assessing adsorption, distribution, metabolisation and excretion of the substance. Based on effects seen in the human health toxicity studies and physico-chemical parameters Nebulone is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Introduction:The test material Nebulone (Cas no. 365411-50-3) has tricyclic-ring consisting of a hexyl-ring with two oxygens separated by a carbon (acetal group), a hexyl ring with a double bone which is part of the 2nd pentyl ring. On this pentyl ring methyl groups are attached to each C atom. The substance is a solid but handled as a liquid. Its melting point is 38oC and it has a molecular weight of 250 that does not preclude absorption. The test material is not likely to hydrolyse under physiological circumstance and has a low volatility (0.36 Pa).
Absorption:Oral: The results of the 28-day repeat oral dose (gavage) and oral (dietary) reproductive toxicity show that the substance is being absorbed by the gastro-intestinal tract following oral administration because minimal effects on a range of parameters are seen at the high dose of 1000 mg/kg bw resulting in a NOAEL of 150 mg/kg bw. The relatively low molecular weight and the moderate octanol/water partition coefficient (Log Kow 4.29) and water solubility (13.3 mg/l) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This shows that the substance is likely to be absorbed orally and therefore the oral absorption is expected to be > 50%.
Skin: The substance is not a skin and eye irritant and is a weak skin sensitizer, which indicates that absorption occurs. Also based on the physico-chemical characteristics of the substance, handled as a liquid, its molecular weight (250), log Kow (4.29) and water solubility (13.3mg/l), indicate that (some) dermal absorption is likely to occur. The optimal MW and log Kow for dermal absorption is < 100 and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). The substance is just outside this range optimal range and therefore the skin absorption is not expected to exceed 50%.
Lungs: Absorption via the lungs is also indicated based on these physico-chemical properties. Though the inhalation exposure route is thought minor, because of its low volatility (0.36 Pa), the octanol/water partition coefficient (4.29), indicates that inhalation absorption is possible. The blood/air (B/A) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. (2012) have developed B/A model for humans using the most important and readily available parameters:
Log P (BA) = 6.96 – 1.04 Log (VP) – 0.533 (Log) Kow – 0.00495 MW.
For Nebulone the B/A partition coefficient would result in:
Log P (BA) = 6.96 – 1.04 x 0.36 – 0.533 x 4.29 – 0.00495 x 250 = 6.96 – 0.416-2.3-1.24 = 3
This means that the substance has a tendency to go from air into the blood. It should, however, be noted that this regression line is only valid for substances which have a vapour pressure > 100 Pa. Despite Nebulone being somewhat out of the applicability domain and the exact B/A may not be fully correct, it can be seen that the substance will be readily absorbed via the inhalation route and could be close to 100%.
Distribution:The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. Due to the expected metabolisation the substance as such would limitedly accumulate in the body fat.
Metabolism:The metabolisation of Nebulone is assessed using OECD Toolbox 3 liver metabolism simulator. The metabolites are presented below as an example in which an OH group is attached to one of the methyl groups of the pentyl ring. Such an OH group maybe attached to every methyl group and/or an acid may be formed. Another type of metabolite is the opening of the hexyl-ring with the two oxygens. These oxygens may become aldehydes or acids. These metabolites are expected to be more water soluble, have a lower Log Kow values and will therefore be more easily excreted.
Fig. 1 The theoretical metabolisation of Nebulone is expected to result via hydroxylation of the methyl groups of the pentyl-ring and/or an acid group can be formed at C4 as predicted by the OECD Toolbox 3.0 liver metabolism simulator. Another metabolic route is the opening of the hexyl-ring with the oxygens resulting in aldehydes and/or acidic groups.
Excretion:Effects seen in the kidney of the rats indicate that one route of excretion is through the urine. Any unabsorbed substance will be excreted via the faeces.
Discussion:The substance is expected to be readily absorbed, orally and via inhalation, based on the human toxicological information and physico-chemical parameters. The substance is expected to be absorbed dermally due to the observed skin sensitization properties. The MW and the log Kow are higher than the favourable range for dermal absorption but significant absorption is likely.
The IGHRC (2006) document of the HSE and mentioned in the ECHA guidance Chapter 8 will be followed to derive the final absorption values for the risk characterisation.
Oral to dermal extrapolation:There are adequate data via the oral route and the critical toxic effect is related to systemic effects and therefore route to route extrapolation is applicable. The toxicity of the substance will be due to the parent compound but also to its metabolites. The overriding principle will be to avoid situations where the extrapolation of data would underestimate toxicity resulting from human exposure to a chemical by the route to route extrapolation. The substance is not expected to be detoxified in the gut because it is hydrolytically stable. Though some first pass effect via the liver may occur the toxicity via the dermal route will not be underestimated because absorption will be slower and the compound will also pass the liver. Therefore it will be assumed that the oral absorption will equal dermal absorption. Using the asymmetric handling of uncertainty the oral absorption will be considered 50% (though likely to be higher) and the dermal absorption will be considered also 50% (though likely to be lower).
Oral to inhalation extrapolation:Though the substance is not a volatile liquid some inhalation exposure will be calculated. The substance is not corrosive to skin and eye and the systemic effects will overrule the effects at the site of contact. In the absence of bioavailability data it is most precautionary that 100% of the inhaled vapour is bioavailable. For the oral absorption 50% has been used for route to route extrapolation to be precautionary for the dermal route. For inhalation absorption 100% will be used for route to route extrapolation, because this will be precautionary for the inhalation route.
Conclusion:Nebulone is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route based on toxicity and physico-chemical data. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
References
Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partition coefficient using basis physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
IGHRC, 2006, Guidelines on route to route extrapolation of toxicity data when assessing health risks of chemicals,http://ieh.cranfield.ac.uk/ighrc/cr12[1].pdf
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.